contusugene ladenovec - Advexin; Gendux; Ad-p53; Adp53; INGN 201; Ad5CMV-p53; RPR/INGN 201; adenovirus vector p53 gene therapy, recombinant; p53 tumor suppressor therapy -- Product Record

p53 Gene Therapy, rDNA/Introgen

    Nomenclature:
      contusugene ladenovec [USAN INN]
      p53 Gene Therapy, rDNA/Introgen [BIO]
      Advexin [TR]
      Gendux [TR EU]
      600735-73-7 [CAS RN]
      Ad-p53 [SY]
      Ad5CMV-p53 [SY]
      Adeno-p53 [SY]
      adenovirus vector p53 gene therapy, recombinant [SY]
      Adp53 [SY]
      INGN 201 [SY]
      INGN-201 [SY]
      p53 tumor suppressor therapy [SY]
      RPR/INGN 201 [SY]

    FDA Class:  Biologic BLA

Index Terms:

  • Product Class Index:
      biopharmaceutical products
      Gene Activation
      recombinant DNA
  • Biological Index:
      acute respiratory distress syndrome (ARDS)
      adenovirus infection prophylaxis
      apheresis (hemapheresis)
      cells, human
      heat treatment (pasteurization)
      human embryonic cells
      keratinocytes, human
      P3x63Ag8.653 myeloma cells
  • Chemical Index:
  • Source/Host/Expression System: adenovirus vector viradeno genether
  • Regulatory/Status Index:
      Cohn Fraction IV
      exempt from CBER lot release requirements
      North American coral snake
      North American coral snake
      orphan status
      EU002 EU application pending
      UM999 Not Available/Not Marketed in US
      US002 FDA application pending
      EM999 Not Available/Not Marketed in EU